Cellular Reprogramming

Featured Literature: Cellular Reprogramming

Explore all of our reprogramming based products, including STEMCCA, reprogramming boost kits and characterization tools in our Reprogramming Cell Fate and Function Brochure.
The discovery that somatic cells could revert back to pluripotent like cells (induced pluripotent stem cells) in 2006 by Shinya Yamanaka created an entirely new area of stem cell biology. IPS cells removed the ethical concerns associated with embryonic stem cells and allowed scientists to model human diseases that were previously impossible to model such as Alzheimer’s, Parkinson’s and autism. The current science of inducing pluripotency in cells has yielded practical technologies and protocols for a new generation of applied stem cell research. These innovations have advanced all steps of the reprogramming workflow: iPS cell generation; iPS cell culture; iPS cell characterization; and iPS cell differentiation. iPS cell clones must be carefully characterized before any application in diagnosis or therapy. Following characterization of ES-like state, the iPS cells can be guided down distinct differentiation pathways using various growth factors, small molecules, or other extracellular microenvironment manipulations.
Stem Cell Research Cellular Reprogramming

EMD Millipore is dedicated to developing and refining these induced pluripotent stem (iPS) cell technologies. With EMD Millipore’s comprehensive portfolio of reagents and antibodies, including the expertise of Upstate®, Chemicon, and Calbiochem brands, researchers now have reliable, high-quality solutions for cellular reprogramming.